Skip to main content
OpenTrials
Completed

NCT Number: NCT04925232

Transcranial Magnetic Stimulation For Visual Snow Syndrome

This study aims to investigate the feasibility of the use of repetitive transcranial magnetic stimulation (rTMS) for symptoms associated with Visual Snow syndrome (VS).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Visual Snow Syndrome

Age range

19 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Colorado School of Medicine Anschutz Medical Campus

Aurora, Colorado, 80045, United States

About this study

The study will gather information about the treatment of up to 10 people with VS using rTMS. Treated participants will undergo 10 sessions of rTMS administered 5 times a week over 2 weeks. All visits will take place in the University of Colorado School of Medicine NeuroMag/Transcranial Magnetic Stimulation laboratory on University of Colorado Anschutz Medical Campus.

The specific aims for this feasibility study include:

  • Determine whether any participant experiences untoward effects of rTMS in the setting of visual snow syndrome and determine the potential drop-out rate of larger study.
  • Determine the performance of a novel scale (Colorado Visual Snow Scale) and two three psychophysical visual processing tasks
  • Determine the standard deviation and test-retest reliability for the novel scale and two visual processing tasks
  • Determine whether the visual processing tasks perform similar to performance found by the developer
  • Describe changes in outcome measures between pre- and post-treatment with rTMS

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A diagnosis of VS that meets International Headache Society criteria
  • Able to provide meaningful informed consent
  • Visual snow must be present for more than three months and must be persistent (i.e. continuous)
  • A prior clinical Brain MRI with and without contrast done in the past 3 years that does not show signs of clinically significant brain lesions (no evidence of multiple sclerosis, stroke, brain tumor, cortical heterotopia or other cortical developmental abnormalities, arteriovenous malformation, etc…)

Exclusion criteria

  • Syndrome meeting criteria for Hallucinogen-persisting perception disorder
  • Prior treatment with TMS for any disorder
  • Epilepsy, family history of epilepsy, or personal history of seizure
  • Any medical condition or medication that increases the risk of seizure
  • Pacemaker or other implantable medical device
  • Metal in the skull, not including the mouth
  • Unstable cardiac, pulmonary, or other systemic illness
  • Pregnancy
  • Bipolar disorder
  • History of suicidality

Treatment and study plan

Transcranial Magnetic Stimulation Device

Device

Five days a week for 2 consecutive weeks, participants will have repetitive TMS at specific paramaters

Other names: TMS

Primary outcomes

  1. TMS Side Effect Questionnaire

    Time frame: Week 1

    The TMS Side Effect Questionnaire queries participants for specific and potential side effects related to TMS. It also allows for open ended answers regarding potential side effects from TMS. The percent of participants experiencing adverse events directly related to treatment will be reported.

  2. TMS Side Effect Questionnaire

    Time frame: Week 2

    The TMS Side Effect Questionnaire queries participants for specific and potential side effects related to TMS. It also allows for open ended answers regarding potential side effects from TMS.The percent of participants experiencing adverse events directly related to treatment will be reported.

  3. TMS Side Effect Questionnaire

    Time frame: Month 1

    The TMS Side Effect Questionnaire queries participants for specific and potential side effects related to TMS. It also allows for open ended answers regarding potential side effects from TMS.The percent of participants experiencing adverse events directly related to treatment will be reported.

  4. TMS Side Effect Questionnaire

    Time frame: Month 3

    The TMS Side Effect Questionnaire queries participants for specific and potential side effects related to TMS. It also allows for open ended answers regarding potential side effects from TMS. The percent of participants experiencing adverse events directly related to treatment will be reported.

  5. Visual Noise Task

    Time frame: Week 1

    This task will assess physiological properties of the visual system related to visual noise and will measure luminance increment detection threshold in a noise task with scores from 0-7, with higher scores considered poorer performance.

  6. Visual Noise Task

    Time frame: Week 2

    This task will assess physiological properties of the visual system related to visual noise and will measure luminance increment detection threshold in a noise task with scores from 0-7, with higher scores considered poorer performance.

  7. Visual Noise Task

    Time frame: Month 1

    This task will assess physiological properties of the visual system related to visual noise and will measure luminance increment detection threshold in a noise task with scores from 0-7, with higher scores considered poorer performance.

  8. Visual Noise Task

    Time frame: Month 3

    This task will assess physiological properties of the visual system related to visual noise and will measure luminance increment detection threshold in a noise task with scores from 0-7, with higher scores considered poorer performance.

  9. Visual Contrast Task

    Time frame: Week 1

    This task will assess physiological properties of the visual system related to contrast and will measure the suppression index for a center-surround suppression task with scores from -1.00 to +1.00, with lower scores considered poorer performance

  10. Visual Contrast Task

    Time frame: Week 2

    This task will assess physiological properties of the visual system related to contrast and will measure the suppression index for a center-surround suppression task with scores from -1.00 to +1.00, with lower scores considered poorer performance

  11. Visual Contrast Task

    Time frame: Month 1

    This task will assess physiological properties of the visual system related to contrast and will measure the suppression index for a center-surround suppression task with scores from -1.00 to +1.00, with lower scores considered poorer performance

  12. Visual Contrast Task

    Time frame: Month 3

    This task will assess physiological properties of the visual system related to contrast and will measure the suppression index for a center-surround suppression task with scores from -1.00 to +1.00, with lower scores considered poorer performance

  13. Global Motion Task

    Time frame: Week 1

    Each test will assess physiological properties of the visual system related to global motion and measure pattern coherence threshold for global motion task with scores from 0.00 to 1.00, with higher thresholds considered poorer performance.

  14. Global Motion Task

    Time frame: Week 2

    Each test will assess physiological properties of the visual system related to global motion and measure pattern coherence threshold for global motion task with scores from 0.00 to 1.00, with higher thresholds considered poorer performance.

  15. Global Motion Task

    Time frame: Month 1

    Each test will assess physiological properties of the visual system related to global motion and measure pattern coherence threshold for global motion task with scores from 0.00 to 1.00, with higher thresholds considered poorer performance.

  16. Global Motion Task

    Time frame: Month 3

    Each test will assess physiological properties of the visual system related to global motion and measure pattern coherence threshold for global motion task with scores from 0.00 to 1.00, with higher thresholds considered poorer performance.

  17. Colorado Visual Snow Symptom Scale

    Time frame: Week 1

    Colorado Visual Snow Scale is a novel scale created for this study and to investigate its use in measure symptom severity. There are 11 subscales: Visual Static, Afterimages, Trails, Blue Field Entoptic Phenomenon, Floaters, Night Vision Problems, Tinnitus, Feeling of Detachment, Anxiety, Depression, Sleep Issues. Each section assess symptom severe, impact on vision, impact on daily activities, and ability to drive with scale of 0-10 wiht 10 being more severe or impairing the symptom. Total score for each subscale can range from 0-40 and total score overall can range from 0-440 and the higher the score the more severe or impairing the symptoms.

  18. Colorado Visual Snow Symptom Scale

    Time frame: Week 2

    Colorado Visual Snow Scale is a novel scale created for this study and to investigate its use in measure symptom severity. There are 11 subscales: Visual Static, Afterimages, Trails, Blue Field Entoptic Phenomenon, Floaters, Night Vision Problems, Tinnitus, Feeling of Detachment, Anxiety, Depression, Sleep Issues. Each section assess symptom severe, impact on vision, impact on daily activities, and ability to drive with scale of 0-10 wiht 10 being more severe or impairing the symptom. Total score for each subscale can range from 0-40 and total score overall can range from 0-440 and the higher the score the more severe or impairing the symptoms.

  19. Colorado Visual Snow Symptom Scale

    Time frame: Month 1

    Colorado Visual Snow Scale is a novel scale created for this study and to investigate its use in measure symptom severity. There are 11 subscales: Visual Static, Afterimages, Trails, Blue Field Entoptic Phenomenon, Floaters, Night Vision Problems, Tinnitus, Feeling of Detachment, Anxiety, Depression, Sleep Issues. Each section assess symptom severe, impact on vision, impact on daily activities, and ability to drive with scale of 0-10 wiht 10 being more severe or impairing the symptom. Total score for each subscale can range from 0-40 and total score overall can range from 0-440 and the higher the score the more severe or impairing the symptoms.

  20. Colorado Visual Snow Symptom Scale

    Time frame: Month 3

    Colorado Visual Snow Scale is a novel scale created for this study and to investigate its use in measure symptom severity. There are 11 subscales: Visual Static, Afterimages, Trails, Blue Field Entoptic Phenomenon, Floaters, Night Vision Problems, Tinnitus, Feeling of Detachment, Anxiety, Depression, Sleep Issues. Each section assess symptom severe, impact on vision, impact on daily activities, and ability to drive with scale of 0-10 wiht 10 being more severe or impairing the symptom. Total score for each subscale can range from 0-40 and total score overall can range from 0-440 and the higher the score the more severe or impairing the symptoms.

  21. Drop out rate

    Time frame: Month 3

    The number of participants who drop out will be determined at the end of the study.

  22. Visual Functional Quality Scale (VFQ-25)

    Time frame: Week 1

    The VFQ-25 is a reliable and valid 25-item version of the 51-item National Eye Institute Visual Function Questionnaire (NEI-VFQ) and it is useful in clinical trials to measure quality of visual functioning. Scores range from 0-100 with higher scores indicating better quality visual functioning in everyday activities.

  23. Visual Functional Quality Scale (VFQ-25)

    Time frame: Week 2

    The VFQ-25 is a reliable and valid 25-item version of the 51-item National Eye Institute Visual Function Questionnaire (NEI-VFQ) and it is useful in clinical trials to measure quality of visual functioning. Scores range from 0-100 with higher scores indicating better quality visual functioning in everyday activities.

  24. Visual Functional Quality Scale (VFQ-25)

    Time frame: Month 1

    The VFQ-25 is a reliable and valid 25-item version of the 51-item National Eye Institute Visual Function Questionnaire (NEI-VFQ) and it is useful in clinical trials to measure quality of visual functioning. Scores range from 0-100 with higher scores indicating better quality visual functioning in everyday activities.

  25. Visual Functional Quality Scale (VFQ-25)

    Time frame: Month 3

    The VFQ-25 is a reliable and valid 25-item version of the 51-item National Eye Institute Visual Function Questionnaire (NEI-VFQ) and it is useful in clinical trials to measure quality of visual functioning. Scores range from 0-100 with higher scores indicating better quality visual functioning in everyday activities.

  26. General Anxiety Disorder Scale (GAD-7)

    Time frame: Week 1

    Screening questionnaire that measures the degree of anxiety with scores ranging from 0-21 and higher scores indicate greater anxiety. Scores of 5, 10, and 15 can be interpreted as representing mild, moderate, and severe levels of anxiety.

  27. General Anxiety Disorder Scale (GAD-7)

    Time frame: Week 2

    Screening questionnaire that measures the degree of anxiety with scores ranging from 0-21 and higher scores indicate greater anxiety. Scores of 5, 10, and 15 can be interpreted as representing mild, moderate, and severe levels of anxiety.

  28. General Anxiety Disorder Scale (GAD-7)

    Time frame: Month 1

    Screening questionnaire that measures the degree of anxiety with scores ranging from 0-21 and higher scores indicate greater anxiety. Scores of 5, 10, and 15 can be interpreted as representing mild, moderate, and severe levels of anxiety.

  29. General Anxiety Disorder Scale (GAD-7)

    Time frame: Month 3

    Screening questionnaire that measures the degree of anxiety with scores ranging from 0-21 and higher scores indicate greater anxiety. Scores of 5, 10, and 15 can be interpreted as representing mild, moderate, and severe levels of anxiety.

Sponsors and collaborators

Lead sponsor

University of Colorado, Denver

Other

Registry information

Official study title

Transcranial Magnetic Stimulation for Visual Snow Syndrome: An Open-Label Feasibility Treatment Trial

Acronym: TMSVS

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Jun 14, 2021
Registry last updated
May 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.